Pirfenidone News and Research

RSS

Machine learning identifies natural compound to treat lung disease

A new study published in Engineering has combined machine learning (ML) and experimental validation to identify dihydromyricetin (DHM), a natural flavonoid, as a potent inhibitor of the TGF-β/ALK5 signaling cascade with therapeutic potential for idiopathic pulmonary fibrosis (IPF).

16 Jun 2026

New study solves lung transplant rejection mystery

More than 50% of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet the reason why this is such a prevalent complication has remained a medical mystery.

22 Oct 2025

Targeting TGF-β signaling as a strategy to treat liver fibrosis

Liver fibrosis, a pathological scarring process resulting from chronic liver injury, represents a significant global health burden due to its potential progression to cirrhosis and hepatocellular carcinoma.

25 Sep 2025

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.

17 Jun 2025

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial. The highest dose group demonstrated a trend toward increased forced vital capacity, especially among patients not receiving standard antifibrotic therapy, supporting further clinical investigation.

4 Jun 2025

Global clinical trial tests two anti-inflammatory drugs for long COVID

Spanning four continents and enrolling hundreds of people, a new clinical trial will test the effectiveness of two anti-inflammatory medicines as potential treatments for long COVID, scientists from Western University and the Schmidt Initiative for Long Covid (SILC) announced today.

24 Apr 2025

Advancing pulmonary fibrosis treatment through targeted drug delivery

Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and tissue scarring, and leading to impaired lung function and respiratory failure.

14 Apr 2025

Blocking Piezo2 may offer a new therapeutic approach for pulmonary fibrotic diseases

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical forces in tissues including stress, strain, and stiffness.

25 Mar 2025

In silico docking of clinically approved drugs against the SARS-CoV-2 receptor-binding domain

Announcing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, resulting in the coronavirus disease 2019 (COVID-19) pandemic.

4 Feb 2025

New study offers hope for extending ovarian healthspan and function

A woman's ovaries are like a factory where eggs grow and produce hormones that regulate everything from menstruation and pregnancy to bone density and mood.

17 Sep 2024

U-M study reveals potential pathway to reverse lung fibrosis

The most common type of lung fibrosis - scarring of the lungs -- is idiopathic, meaning of unknown cause.

13 Apr 2024

UVA scientists develop new approach to machine learning for identifying heart drug

University of Virginia scientists have developed a new approach to machine learning – a form of artificial intelligence – to identify drugs that help minimize harmful scarring after a heart attack or other injuries.

5 Feb 2024

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 14, entitled, "Human senescent fibroblasts trigger progressive lung fibrosis in mice."

31 Jul 2023

3D-printed vaginal ovules offer promising treatment for endometriosis

3D-printed vaginal ovules offer controlled release and targeted treatment, showing promise for conditions like endometriosis.

20 Jun 2023

Understanding post-COVID interstitial lung disease: Causes, treatment options

After being hospitalized for three months with COVID-19 and double pneumonia in 2020, Houston police officer Hito Bazan awoke one morning to discover that he couldn't talk, eat, walk, or most importantly, breathe. Bazan was diagnosed with interstitial lung disease (ILD) known as pulmonary fibrosis (PF).

27 Apr 2023

3D cell culture system tests how inhibiting fibroblast activities can help treat lung cancer

Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.

28 Mar 2023

Anti-fibrotics found to be safe, effective for interstitial lung disease in patients with rheumatoid arthritis

For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).

22 Sep 2022

Y chromosome loss in men can lead to deadly heart failure, research shows

The loss of the male sex chromosome as many men age causes the heart muscle to scar and can lead to deadly heart failure, new research from the University of Virginia School of Medicine shows.

14 Jul 2022

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

6 Aug 2020